Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of a Securities Class Action Against Antares Pharma, Inc. (ATRS)

NEW YORK, Oct. 31, 2017

Antares is a specialty pharmaceutical company that develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies.  Antares's product Xyosted has been among the Company's lead product candidates.

The lawsuit claims that Antares made false and misleading statements and/or failed to disclose that Antares had provided insufficient data to the U.S. Food and Drug Administration ("FDA") in connection with its New Drug Application ("NDA") for Xyosted and had overstated the approval prospects for Xyosted.

On October 12, 2017, after the market closed, Antares disclosed that on October 11, 2017, it had received a letter from the FDA stating that the agency had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Xyosted.

On this news, the price of Antares shares fell $1.41, or 37.80%, to close at $2.32 on October 13, 2017.

Then, on October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding the NDA for Xyosted, "indicat[ing] that the FDA cannot approve the NDA in its present form" due to concerns that Xyosted "could cause a clinically meaningful increase in blood pressure" and noting concerns "regarding the occurrence of depression and suicidality."

What You Can Do